The Jackson Laboratory completed its acquisition of the New York Stem Cell Foundation, combining JAX’s genetics infrastructure with NYSCF’s human stem cell platforms. The transaction creates an integrated research engine aimed at accelerating translational programs and precision therapy development, with combined assets spanning disease models, iPSC platforms, and translational pipelines. Executives highlighted the deal’s potential to shorten preclinical timelines and enhance patient‑relevant modeling. The merger underscores institutional consolidation as a route to scale advanced cellular models for therapeutic discovery.